Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Reports Mixed Second Quarter Results

This article was originally published in The Gray Sheet

Executive Summary

Spine revenues of $782 million, for instance, declined 5% on a constant currency basis, while coronary revenues rose by 19% to $429 million, driven by global sales of the firm’s Resolute Integrity zotarolimus-eluting stent.

Advertisement

Related Content

FDA Audit Slows Down Medtronic Launch Plans For Low-Glucose-Suspend Diabetes System
Medtronic Puts Spine Business Under Close Evaluation

Topics

Advertisement
UsernamePublicRestriction

Register

MT031754

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel